Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
New England Journal of Medicine2021Vol. 384(22), pp. 2161–2163
Citations Over TimeTop 10% of 2021 papers
Thandeka Moyo-Gwete, Mashudu Madzivhandila, Zanele Makhado, Frances Ayres, Donald Mhlanga, Brent Oosthuysen, Bronwen E. Lambson, Prudence Kgagudi, Houriiyah Tegally, Arash Iranzadeh, Deelan Doolabh, Lynn Tyers, Lionel R. Chinhoyi, Mathilda Mennen, Sango Skelem, Gert Marais, Constantinos Kurt Wibmer, Jinal N. Bhiman, Veronica Ueckermann, Theresa M. Rossouw, Michael T. Boswell, Túlio de Oliveira, Carolyn Williamson, Wendy A. Burgers, Ntobeko Ntusi, Lynn Morris, Penny L. Moore
Abstract
Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant Convalescent serum from persons who had recovered from infection with 501Y.V2 (B.1.351), a SARS-CoV-2 variant first identified in S...
Related Papers
- → Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV)(2020)32 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management(2022)21 cited
- → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited